beclomethasone dipropionate hfa
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
QVAR REDIHALER is a metered-dose inhaler containing beclomethasone dipropionate HFA, a corticosteroid used to treat asthma by reducing airway inflammation. It is delivered via inhalation and represents a reformulated version of earlier beclomethasone products with improved delivery technology. The drug addresses maintenance asthma control across mild to moderate disease severity.
The product is in peak commercial stage with $49M in annual Part D spending, suggesting a stable, mature brand requiring experienced commercial teams focused on market maintenance and managed care strategy.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on QVAR REDIHALER positions professionals in a stable, mature franchise with solid reimbursement and predictable revenue, ideal for brand management and managed care expertise. The lack of active clinical development and zero linked job openings suggest the team size is established and growth roles are limited, making this suitable for consolidation and optimization-focused careers rather than expansion-phase opportunities.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo